Kymera Therapeutics (KYMR) Projected to Post Earnings on Wednesday

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) is expected to announce its Q2 2025 earnings results before the market opens on Wednesday, August 6th. Analysts expect the company to announce earnings of ($0.84) per share and revenue of $17.37 million for the quarter.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its quarterly earnings data on Friday, May 9th. The company reported ($0.82) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.92) by $0.10. Kymera Therapeutics had a negative net margin of 409.07% and a negative return on equity of 30.11%. The business had revenue of $22.10 million during the quarter, compared to the consensus estimate of $11.38 million. During the same period in the prior year, the firm posted ($0.69) EPS. The firm's quarterly revenue was up 114.6% compared to the same quarter last year. On average, analysts expect Kymera Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Kymera Therapeutics Price Performance

Shares of Kymera Therapeutics stock traded down $0.79 on Friday, reaching $42.96. 393,426 shares of the company traded hands, compared to its average volume of 748,569. Kymera Therapeutics has a 52 week low of $19.44 and a 52 week high of $53.27. The company has a 50 day moving average of $43.58 and a 200 day moving average of $36.55. The firm has a market capitalization of $2.80 billion, a PE ratio of -13.86 and a beta of 2.18.

Analyst Ratings Changes

A number of research analysts have recently weighed in on KYMR shares. Oppenheimer reissued an "outperform" rating and set a $53.00 target price (down from $56.00) on shares of Kymera Therapeutics in a research report on Friday, June 27th. Wall Street Zen raised shares of Kymera Therapeutics from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. BTIG Research reissued a "buy" rating and set a $59.00 target price on shares of Kymera Therapeutics in a research report on Thursday, June 26th. JPMorgan Chase & Co. increased their target price on shares of Kymera Therapeutics from $57.00 to $64.00 and gave the company an "overweight" rating in a research report on Tuesday, June 3rd. Finally, B. Riley raised shares of Kymera Therapeutics to a "strong-buy" rating and set a $60.00 price objective for the company in a report on Wednesday. Two research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $59.11.

Insider Transactions at Kymera Therapeutics

In other news, CEO Nello Mainolfi sold 30,000 shares of the firm's stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $49.00, for a total transaction of $1,470,000.00. Following the sale, the chief executive officer owned 660,482 shares in the company, valued at approximately $32,363,618. This trade represents a 4.34% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Bvf Partners L. P/Il acquired 317,167 shares of the stock in a transaction dated Monday, June 30th. The shares were bought at an average price of $44.00 per share, for a total transaction of $13,955,348.00. Following the transaction, the director owned 2,798,795 shares in the company, valued at approximately $123,146,980. This represents a 12.78% increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders sold 48,349 shares of company stock worth $2,334,301. 16.01% of the stock is owned by corporate insiders.

Institutional Trading of Kymera Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Kymera Therapeutics by 6.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,793 shares of the company's stock valued at $849,000 after buying an additional 1,833 shares in the last quarter. Millennium Management LLC raised its position in shares of Kymera Therapeutics by 340.4% during the 1st quarter. Millennium Management LLC now owns 510,480 shares of the company's stock valued at $13,972,000 after buying an additional 394,562 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Kymera Therapeutics by 121.5% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 896,404 shares of the company's stock valued at $24,535,000 after buying an additional 491,737 shares in the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.